Document is current
Any future updates will be listed below
-
Authors
Qiu, Baiyu
Zandkarimi, Fereshteh https://orcid.org/0000-0001-8618-3669
Saqi, Anjali
Castagna, Candace https://orcid.org/0000-0003-2410-9361
Tan, Hui
Sekulic, Miroslav
Miorin, Lisa
Hibshoosh, Hanina
Toyokuni, Shinya https://orcid.org/0000-0002-5757-1109
Uchida, Koji
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA209896)
- License Information
-
More Information
Article History
Received: 18 August 2023
Accepted: 18 April 2024
First Online: 20 May 2024
Competing interests
: B.R.S. is an inventor on patents and patent applications involving ferroptosis; co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP. B.R.S. and H.T. are inventors on a patent application related to ferrostatin-1 analog development. B.Q. is now a Post Doc Scientist at Gilead Sciences, Inc. The remaining authors declare no competing interests.
: This study included local researchers throughout the research process. The roles and responsibilities were agreed amongst all collaborators ahead of the research. This study did not result in stigmatization, incrimination, discrimination, or otherwise personal risk to participants. This research involved safety risk to researchers handling SARS-CoV-2 infected samples, but all procedures were approved by IRB and IACUC protocols, and the study was performed in biosafety cabinets to ensure no exposure to active viruses. Local and regional research relevant to this study were included in citations.
